Probiotics

Probiotics are live micro-organisms, mostly Lactobacillus and Bifidobacterium bacteria and sometimes the yeast Saccharomyces boulardii, taken by mouth as supplements, drops or fermented foods. The idea behind using them for Atopic Dermatitis is that children with eczema have a different gut flora from children without it. Changing the gut bacteria might then calm the overactive Th2 Immune Response and the gut inflammation thought to feed skin inflammation (Cochrane 2018; NCCIH). The questions “do probiotics treat a toddler’s existing eczema?” and “can probiotics in pregnancy or early infancy stop eczema developing?” need separate answers. The evidence on each is very different.

Probiotics [relates] Atopic Dermatitis Probiotics [relates] Th2 Immune Response Probiotics [part-of] Herbal and Home Remedies for Eczema

Treatment: little or no benefit. The Cochrane review by Makrgeorgou et al. (2018) pooled 39 RCTs with 2,599 participants, most of them children. It found that currently available probiotics “probably make little or no difference” to eczema symptoms rated by patients or parents (moderate-quality evidence) and bring no quality-of-life benefit. The average SCORAD fell by 3.91 points, which is below the 8.7-point minimal clinically important difference. The authors called probiotic treatment of eczema “currently not evidence-based”. NCCIH’s general probiotics page cites a 2017 review of 13 studies (1,271 infants and children) that likewise “did not find consistent evidence of a beneficial effect”. The American Academy of Dermatology does not recommend probiotics for established AD. NCCIH’s clinical digest is more hopeful about a subgroup, citing a 2021 RCT in under-2s with cow’s-milk allergy. That disagreement stays open (below).

Cochrane [contradicts] Probiotics American Academy of Dermatology [opposes] Probiotics Probiotics [relates] Food Allergy

Conflict: [Makrgeorgou et al., Cochrane, 2018] says currently available probiotics probably make little or no difference to eczema symptoms and that their use “is currently not evidence-based”. [NCCIH Clinical Digest, n.d. (cites 2021 RCT)] says “evidence suggests that probiotics may be effective for some, but not all, children”. It cites a 2021 RCT in children under 2 with cow’s-milk allergy in which more children improved on L. rhamnosus + L. casei than on placebo. Unresolved — add to open_questions.

Prevention: a weak signal, mostly from mothers. The 2015 World Allergy Organization–McMaster GLAD-P guideline found that probiotics do not reduce allergy in general. Because eczema prevention seemed to bring a net benefit, it suggested probiotics for three groups: pregnant women at high risk of an allergic child (eczema RR 0.72, 95% CI 0.61–0.85), breastfeeding women of high-risk infants (RR 0.61), and high-risk infants themselves (RR 0.81, 0.70–0.94). Every recommendation was conditional and based on very low-quality evidence. “High risk” meant a parent or sibling with eczema, asthma, hay fever or food allergy. An earlier meta-analysis of 14 RCTs (Pelucchi 2012) found RR 0.79 (0.71–0.88), with a similar effect whoever took the probiotic. Later reviews narrow this down. The 2025 Cochrane review (Wang et al.; 24 studies, 7,077 mother–infant pairs) concluded that probiotics given to infants in the first 6 months “may slightly reduce” eczema by age 2. It rated the certainty low and found the evidence insufficient for routine use. A 2026 meta-analysis of 18 RCTs (10,195 infants) restricted to supplementation started in infancy found no protective effect (RR 0.94, 0.72–1.25; I² 72.8%). Its authors argue that the earlier 20–30% risk reductions came mainly from perinatal regimens that also treated the mother (Wei & Ding 2026). None of this applies to a toddler who already has eczema. The window these trials target is pregnancy and the first months of life.

World Allergy Organization [supports] Probiotics Probiotics [prevents] Atopic Dermatitis Cochrane [relates] Probiotics Prebiotics and Synbiotics [relates] Probiotics

Conflict: [WAO GLAD-P, Fiocchi et al., 2015] suggests giving probiotics directly to high-risk infants, citing reduced eczema (RR 0.81), and [Pelucchi et al., 2012] found the effect “similar regardless of… the subject(s) receiving probiotics”. [Wei & Ding, J Int Med Res, 2026] found infant-only supplementation does not prevent AD (RR 0.94, 0.72–1.25) and that earlier benefit was driven by maternal-plus-infant regimens. Unresolved — add to open_questions.

Strain heterogeneity. “Probiotic” is not one treatment. NCCIH stresses that if one Lactobacillus strain helps, it “doesn’t necessarily mean that another kind of Lactobacillus or any of the Bifidobacterium probiotics would do the same thing”. The WAO panel could not analyse individual species or strains. It flagged uncertainty about dose and about single strains versus mixtures. The heterogeneity in the 2026 meta-analysis (I² ≈ 73%) is consistent with strains, doses and timing that behave differently. As a result, a pooled null result does not rule out a narrow benefit from one specific strain. It also means a product label cannot be matched to the trials that showed an effect. Supplements are not regulated like medicines, so the strain and dose in a shop product may not match any trial.

Probiotics [relates] Skin Microbiome

Toddler safety. In healthy children the usual effects are mild GI upset (diarrhoea, constipation, colic). Cochrane 2018 found no clear rise in adverse events. Cochrane 2025 found “little to no difference” in infection with probiotic bacteria and no serious adverse events in infant trials. The organism itself can, rarely, invade the bloodstream (bacteraemia, fungaemia or sepsis). NCCIH reports severe and fatal infections in premature infants, and the FDA warned clinicians about this in 2023. The risk is greater “in people with severe illnesses or compromised immune systems”. The WAO recommendations explicitly exclude immunocompromised mothers and infants.

Probiotics in immunocompromised or seriously ill children

Do not give probiotic supplements to a toddler who is immunocompromised, on immunosuppressants (see Systemic Immunosuppressants), has a central line, is seriously ill in hospital, or was born very premature and is still under specialist care, unless that specialist advises it. Rare but potentially fatal bloodstream infections from the probiotic organism have been reported (NCCIH; FDA 2023).

Probiotics [relates] Systemic Immunosuppressants FDA [regulates] Probiotics

What parents report (evidence: anecdotal). The Reddit API returned errors this round, so these reports come from threads already saved in the vault. A parent of an exclusively breastfed 4-month-old wrote: “I’ve had him on a probiotic for a month and that hasn’t seemed to help” (r/beyondthebump, raw/food-allergy/source-10). In an r/eczema thread, one parent relayed that their child’s dermatologist said “the data on probiotics isn’t clear enough at this point to recommend but lots of research happening now” (raw/contact-allergy/source-9). An adult r/eczema poster called a daily probiotic or kefir a “game-changer” that “reduces the frequency and severity of flares” (raw/nmt-perioral/source-8). These reports are mixed and uncontrolled. They match the trial picture: some families notice nothing, and the occasional strong responder cannot be told apart from natural waxing and waning.

Probiotics [relates] Elimination Diets

Connections

• Herbal and Home Remedies for Eczema — listed remedy; little/no benefit, contested, source: Cochrane 2018; NCCIH
• Cochrane — treatment review (2018) null; infant prevention review (2025) low-certainty slight benefit, source: Makrgeorgou 2018; Wang 2025
• World Allergy Organization — 2015 conditional recommendation for perinatal probiotics in high-risk families, source: Fiocchi 2015
• Prebiotics and Synbiotics — related gut-microbiome prevention strategy, source: Osborn & Sinn Cochrane; Wang 2025
• American Academy of Dermatology — does not recommend probiotics for established AD, source: NCCIH digest
• FDA — 2023 warning on probiotic infections in premature infants, source: NCCIH
• Food Allergy — NCCIH-cited 2021 RCT in cow’s-milk-allergic under-2s, source: NCCIH digest
• SCORAD — mean change −3.9, below MCID, source: Cochrane 2018
• Skin Microbiome — gut-skin microbiome rationale, source: Cochrane 2018 background
• Systemic Immunosuppressants — immunosuppressed children at higher risk of probiotic infection, source: NCCIH
• AAD Pediatric Guideline 2026 — conditional rec against probiotic supplementation for AD prevention, source: JAAD 2026